BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23923626)

  • 1. A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment.
    Fürst R; Vollmar AM
    Pharmazie; 2013 Jul; 68(7):478-83. PubMed ID: 23923626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function.
    Field JJ; Kanakkanthara A; Miller JH
    Bioorg Med Chem; 2014 Sep; 22(18):5050-9. PubMed ID: 24650703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progress in the study of tubulin inhibitors].
    Shang H; Pan L; Yang S; Chen H; Cheng MS
    Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tubulin inhibitors: a patent review.
    Liu YM; Chen HL; Lee HY; Liou JP
    Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Inhibition of Spindle Microtubules by a Tubulin-Binding Quinazoline Derivative.
    Sawada JI; Ishii H; Matsuno K; Sato M; Suzuki Y; Asai A
    Mol Pharmacol; 2019 Nov; 96(5):609-618. PubMed ID: 31471455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules.
    Kamath K; Okouneva T; Larson G; Panda D; Wilson L; Jordan MA
    Mol Cancer Ther; 2006 Sep; 5(9):2225-33. PubMed ID: 16985056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 15-Deoxi-Delta(12,14)-prostaglandin J2 is a tubulin-binding agent that destabilizes microtubules and induces mitotic arrest.
    Cocca C; Dorado J; Calvo E; López JA; Santos A; Perez-Castillo A
    Biochem Pharmacol; 2009 Nov; 78(10):1330-9. PubMed ID: 19576185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment.
    Pasquier E; André N; Braguer D
    Curr Cancer Drug Targets; 2007 Sep; 7(6):566-81. PubMed ID: 17896922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
    Jordan MA; Horwitz SB; Lobert S; Correia JJ
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eribulin targets a ch-TOG-dependent directed migration of cancer cells.
    Chanez B; Gonçalves A; Badache A; Verdier-Pinard P
    Oncotarget; 2015 Dec; 6(39):41667-78. PubMed ID: 26497677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotic cell death induction by targeting the mitotic spindle with tubulin-inhibitory indole derivative molecules.
    Di Cesare E; Verrico A; Miele A; Giubettini M; Rovella P; Coluccia A; Famiglini V; La Regina G; Cundari E; Silvestri R; Lavia P
    Oncotarget; 2017 Mar; 8(12):19738-19759. PubMed ID: 28160569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
    Bhattacharyya B; Panda D; Gupta S; Banerjee M
    Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low potency of taxol at microtubule minus ends: implications for its antimitotic and therapeutic mechanism.
    Derry WB; Wilson L; Jordan MA
    Cancer Res; 1998 Mar; 58(6):1177-84. PubMed ID: 9515803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
    Chen JG; Horwitz SB
    Cancer Res; 2002 Apr; 62(7):1935-8. PubMed ID: 11929805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.
    Gupta K; Bishop J; Peck A; Brown J; Wilson L; Panda D
    Biochemistry; 2004 Jun; 43(21):6645-55. PubMed ID: 15157098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460.
    Cenciarelli C; Tanzarella C; Vitale I; Pisano C; Crateri P; Meschini S; Arancia G; Antoccia A
    Apoptosis; 2008 May; 13(5):659-69. PubMed ID: 18386182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-(Naphthalene-1-yl)-6-pyrrolidinyl-4-quinazolinone inhibits skin cancer M21 cell proliferation through aberrant expression of microtubules and the cell cycle.
    Wu YC; Hour MJ; Leung WC; Wu CY; Liu WZ; Chang YH; Lee HZ
    J Pharmacol Exp Ther; 2011 Sep; 338(3):942-51. PubMed ID: 21652781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.